Navigation Links
Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies

BOSTON, Jan. 22 /PRNewswire/ -- Enlight Biosciences LLC, a Boston-based company conceived in partnership with major pharmaceutical companies and academic luminaries, announced today that Johnson & Johnson has joined the initiative. As a partner, Johnson & Johnson will have the opportunity to invest in the development of strategic technologies that have the potential to fundamentally transform drug discovery and development and to apply these pre-competitive technologies to its therapeutic programs. With the participation of Johnson & Johnson, Enlight and its partners are now poised to direct a combined total of up to $52M toward these advances.

(Logo: )

"The Enlight collaboration will benefit from the expansive scope of science and commercial expertise from Johnson & Johnson, as well as from the company's commitment to an open innovation model of supporting universities and medical centers," states Dr. Frank Douglas, Enlight Board Member, PureTech Ventures Senior Partner and former Chief Scientific Officer and Executive Vice President of Aventis.

Enlight proactively addresses critical unmet industry needs with innovations drawn from academic laboratories, startups, and ideas generated internally by the Enlight team. Enlight is focused on areas that include molecular imaging, biologics, and drug formulation and delivery methods, as well as novel synthesis and production technologies and library screening. Enlight evaluates hundreds of technology opportunities per year, selecting only the top one or two to become actively managed programs.

According to Garry A. Neil, M.D., Corporate Vice President, Johnson & Johnson Corporate Office of Science and Technology, "Participation in this initiative will allow us to work with our consortium peers to identify technology needs and influence future industry standards. Our membership aligns with our interest in early-stage discovery platforms, enables us to review promising technologies according to our specifications prior to full development, and supports our commitment to academic research and entrepreneurship."

Enlight's launch was announced in July 2008 by PureTech Ventures, a venture creation firm translating research from top-tier academic institutions into therapies, along with existing Enlight partners Merck & Co., Inc., Pfizer Inc. and Eli Lilly. Enlight's scientific advisory board is led by Nobel Laureate Dr. H. Robert Horvitz, Koch Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute.

Johnson & Johnson will collaborate with the Enlight team and the other pharmaceutical partners to guide Enlight's focus areas and strategic directions, prioritize desired technologies and select active programs. Participation in the Enlight venture will enable the research units of the pharmaceutical companies within the Johnson & Johnson Family of Companies to review a large number of innovative technologies, platforms and tools and to shape the types and focus of such promising research through collaboration with the other partner companies. Johnson & Johnson, like the other partners, will have preferential access to technologies developed by new companies it opts to fund.

"Participation in this collaboration will also enable our research units to make pre-competitive knowledge available across the industry," said Roger Pomerantz, M.D., President, Tibotec Research and Development, and Senior Vice President, Global Virology, Johnson & Johnson. "We are excited about this opportunity to contribute to increasing the standard of medical care, particularly in our focus areas of oncology, cardiovascular and inflammation."

About Enlight

Enlight is a Boston-based company established in partnership with major pharmaceutical companies to develop breakthrough innovations that will fundamentally alter drug discovery and development.

Enlight was co-founded by PureTech Ventures and academic luminaries led by Dr. H. Robert Horvitz, Enlight's SAB Chair, Nobel Laureate, Howard Hughes Investigator, and Koch Professor of Biology at MIT; Dr. Sam Gambhir, Professor of Radiology, Chief of the Division of Nuclear Medicine, Stanford; Dr. Rakesh Jain, Cook Professor of Tumor Biology at MGH and Harvard Medical School; and Dr. Raju Kucherlapati, co-founder of Millennium and Abgenix, Cabot Professor of Genetics at Harvard Medical School.

Enlight's team also includes leading drug developers and innovators, such as Dr. Frank Douglas, PureTech Ventures Senior Partner, former Chief Scientific Officer and Executive Vice President of Aventis; and Dr. Bennett Shapiro, PureTech Ventures Senior Partner, former Executive Vice President of Basic Research and Worldwide Licensing at Merck & Co., Inc.

About PureTech Ventures

PureTech Ventures is a Boston-based venture creation firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health. PureTech's Senior Partners include entrepreneurs and leaders from the top echelon of pharma, biotech and academia.

SOURCE Enlight Biosciences LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Positively Conscious: An Enlightened Look At Life
2. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
3. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
4. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
7. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
8. Anaptys Biosciences Raises Over $33 Million in Series B Financing
10. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: